Syndax Posts $68.7M Q4, $172.4M FY25 Revenue; Revuforj Up 38%, Niktimvo Up 22%
Syndax reported fourth-quarter revenue of $68.7 million and full-year 2025 revenue of $172.4 million, driven by Revuforj net sales of $44.2 million (38% growth) and Niktimvo net sales of $56.0 million (22% growth). The company completed enrollment in its Phase 2 IPF trial with topline data expected in 4Q26.
1. Q4 and Full-Year 2025 Financial Results
Syndax reported $68.7 million in revenue for the fourth quarter of 2025 and $172.4 million for the full year, reflecting continued commercial traction across its oncology portfolio.
2. Strong Product Sales Growth
Revuforj generated net sales of $44.2 million in Q4, up 38% sequentially, and $124.8 million for the year, while Niktimvo net sales reached $56.0 million in Q4, up 22% sequentially, contributing to $42.4 million in collaboration revenue in 2025.
3. Phase 2 IPF Trial Enrollment
The company completed enrollment in its Phase 2 IPF trial of axatilimab and expects topline data in the fourth quarter of 2026, potentially expanding Niktimvo into antifibrotic indications.
4. Investor Call and Growth Outlook
Management will host a conference call at 4:30 PM ET to discuss the results and highlighted multiple growth drivers for 2026, including expanded Revuforj uptake in relapsed/refractory NPM1m AML and post-transplant settings.